Natera,Inc. (NASDAQ:NTRA) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k

7 years ago

Natera,Inc. (NASDAQ:NTRA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry into a Material Definitive Agreement.

On July5, 2017, Natera,Inc. (“Natera”) entered into an amendment (the “Amendment”) to its credit line agreement dated September23, 2015 (together with related documentation, the “Credit Line”) with UBS Bank USA (“UBS”). The Amendment increased the interest rate to one-month LIBOR plus 1.10%, effective July7, 2017, and equaled approximately 2.323% per annum as of July5, 2017.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment which Natera intends to file with the Securities and Exchange Commission as an exhibit to its next Quarterly Report on Form10-Q.

Item 1.01. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form8-K is incorporated herein by reference in this Item 1.01.

About Natera,Inc. (NASDAQ:NTRA)
Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).